OTCPK:MMIR.F

Stock Analysis Report

Executive Summary

MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Latin America and the Caribbean, Europe, the Asia Pacific, and internationally.

Snowflake

Fundamentals

Worrying balance sheet with weak fundamentals.

Risks

  • MedMira has significant price volatility in the past 3 months.
  • MedMira is not covered by any analysts.

Similar Companies

Share Price & News

How has MedMira's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

MMIR.F

0.5%

US Medical Equipment

-0.02%

US Market


1 Year Return

n/a

MMIR.F

9.9%

US Medical Equipment

1.6%

US Market

No trading data on MMIR.F.

No trading data on MMIR.F.


Share holder returns

MMIR.FIndustryMarket
7 Day0%0.5%-0.02%
30 Day-95.0%0.09%2.7%
90 Dayn/a2.0%1.4%
1 Yearn/a10.8%9.9%3.8%1.6%
3 Year-99.7%-99.7%69.0%63.9%45.2%35.8%
5 Year-99.8%-99.8%136.2%109.3%61.8%44.1%

Price Volatility Vs. Market

How volatile is MedMira's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is MedMira undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether MedMira is trading at an attractive price based on the cash flow it is expected to produce in the future. But as MedMira has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of MMIR.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through MedMira regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is MedMira expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MedMira has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of MMIR.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access MedMira's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has MedMira performed over the past 5 years?

10.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

MedMira does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare MedMira's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare MedMira's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if MedMira has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if MedMira has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if MedMira improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is MedMira's financial position?


Financial Position Analysis

MedMira's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

MedMira has no long term commitments.


Debt to Equity History and Analysis

MedMira has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if MedMira's debt level has increased considering it has negative shareholder equity.


Balance Sheet

High level of physical assets or inventory.

MedMira has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

MedMira has less than a year of cash runway based on current free cash flow.

MedMira has less than a year of cash runway if free cash flow continues to reduce at historical rates of -65.3% each year.


Next Steps

Dividend

What is MedMira's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate MedMira's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate MedMira's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as MedMira has not reported any payouts.

Unable to verify if MedMira's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as MedMira has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of MedMira's salary, the management and board of directors tenure and is there insider trading?

6.0yrs

Average management tenure


CEO

Hermes Chan 0

13.2yrs

Tenure

CA$193,126

Compensation

Mr. Hermes Chan Co-Founded MedMira Inc. and has been its President since 2000 and Chief Executive Officer since July 24, 2006. Mr. Chan has been the Chief Executive Officer and President of MedMira Laborat ...


CEO Compensation Analysis

Hermes's remuneration is lower than average for companies of similar size in United States of America.

Hermes's compensation has increased whilst company is loss making.


Management Age and Tenure

6.0yrs

Average Tenure

The average tenure for the MedMira management team is over 5 years, this suggests they are a seasoned and experienced team.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Hermes Chan

    Co-Founder

    • Tenure: 13.2yrs
    • Compensation: CA$193.13k
  • Urs Meile

    Chief Financial Officer

    • Tenure: 5.2yrs
    • Compensation: CA$152.61k
  • Kevin Jones (50yo)

    Head of Commercialization and Senior Director of Sales & Marketing

    • Tenure: 6yrs
  • Stewart McKelvey

    Legal Counsel

    • Tenure: 0yrs

Board Members

  • Hermes Chan

    Co-Founder

    • Tenure: 13.2yrs
    • Compensation: CA$193.13k
  • Steven Cummings

    Director

    • Tenure: 0.3yrs
    • Compensation: CA$64.00k
  • Jianhe Mao

    Director

    • Tenure: 0.3yrs

Company Information

MedMira Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MedMira Inc.
  • Ticker: MMIR.F
  • Exchange: OTCPK
  • Founded: 1993
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$9.875m
  • Listing Market Cap: CA$7.451m
  • Shares outstanding: 658.36m
  • Website: https://medmira.com

Location

  • MedMira Inc.
  • 155 Chain Lake Drive
  • Suite 1
  • Halifax
  • Nova Scotia
  • B3S 1B3
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MIRTSXV (TSX Venture Exchange)YesCommon SharesCACADMar 2000
47MDB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2000
MMIR.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMar 2000

Biography

MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Latin America and the Caribbean, Europe, the Asia  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 01:10
End of Day Share Price2019/09/13 00:00
Earnings2019/04/30
Annual Earnings2018/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.